Immunoglobulin A nephropathy (IgAN) represents the most prevalent form of primary glomerulonephritis globally and constitutes a major contributor to the burden of end-stage renal disease (ESRD) [1]. The clinical trajectory of IgAN varies considerably, yet a significant proportion of patients, estimated between 30 % and 40 %, inevitably progress towards ESRD within two to three decades following initial diagnosis, underscoring the chronic and often progressive nature of this condition [1,2]. For individuals reaching ESRD, kidney transplantation stands as the optimal therapeutic strategy, offering substantial improvements in both survival rates and overall quality of life compared to term dialysis [3].
